IVD’s Next Leap: From Testing to Clinical Decisions

In-vitro diagnostics (IVD) is shifting from “back-end testing” to a front-line decision engine for healthcare systems. The trend isn’t only new assays-it’s the broader move toward faster turnaround, smarter test selection, and data-rich results that clinicians can act on immediately. As hospitals face capacity constraints and payers demand value, IVD is increasingly evaluated by clinical impact per test, not just analytical performance.

Three forces are shaping where the market is heading: first, point-of-care and near-patient testing that reduces patient loss to follow-up and accelerates clinical pathways; second, multiplexing and automation that expand throughput while improving consistency; and third, integration with digital workflows, where test ordering, interpretation, and reporting align with electronic health records and stewardship programs. At the same time, regulatory scrutiny is tightening around usability, quality management, and real-world performance-especially for tests used in critical decision-making.

The most important strategic question for IVD leaders is how to build diagnostic value across the full patient journey. Are we designing tests to answer the right clinical question, in the right setting, with the right operational reliability? In a crowded landscape, differentiation will come from evidence, implementation support, and interoperability-not just technology. I invite peers to discuss: what capability should IVD companies prioritize next-clinical validation, operational deployment, or data integration with care pathways?